

REMARKS/ARGUMENTS

Claims 26-32, 34, 36-38, and 47 are active in this application. The claims have been amended for clarity and to more particularly define the claimed invention. No new matter is added.

Applicants wish to thank Examiner Fronda for the discussions with Applicants' undersigned representative on March 10, 2004 and March 23, 2004. Applicants also thank Biotech Patent Specialist Brian Stanton for providing helpful advice to advance this case to allowance. The substance of these discussions is reflected in the claim amendments submitted herein. Accordingly, favorable reconsideration of the rejections in the Office Action and allowance of all pending claims is requested.


The rejections of Claims 26-32, 34, 36-38 and 47 under 35 U.S.C. § 112, first paragraph (both "written description" and "enablement") are respectfully traversed.

As confirmed during the discussions noted above, the term "attenuated" in the present claims is both described and enabled by the specification as originally filed. All other remaining issues are addressed by the amendment, which the Examiner indicated would place the case in a condition for allowance.

Accordingly, Applicants request withdrawal of both grounds of rejection as well as allowance of this application.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Daniel J. Pereira, Ph.D.
Registration No. 45,518

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413-2220
(OSMMN 08/03)